Erasca Inc

Read Erasca’s Q3 2025 results: patent win for KRAS therapy, 2026 Phase 1 plans, and a multi‑year cash runway—key insights for investors in precision oncology.

Erasca, Inc. is a clinical-stage precision oncology company dedicated to developing innovative cancer treatments through precision medicine, despite facing challenges and uncertainties in the healthcare industry.

Erasca, Inc. has made significant strategic moves, including FDA clearance of its new cancer drug ERAS-0015, and plans to seek partnerships for its phase 3 asset, positioning the company for continued growth in the precision oncology sector.